Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Balloon Angioplasty Catheters Gain Quicker Path To Market Under FDA Rule

This article was originally published in The Gray Sheet

Executive Summary

Standard balloon-tipped angioplasty catheters can enter the market through the 510(k) clearance process, rather than the PMA route, beginning next month

You may also be interested in...

FDA Device Center Gears Up For Product Reclassification Push

FDA is hiring additional staff and channeling user fee funds toward device reclassification efforts now that it has committed itself to more rapidly addressing the subset of Class III devices that still enters the market via 510(k)

Balloon Catheters Might Finally Be Moved Down To 510(k) Status, FDA Signals

FDA says most standard balloon angioplasty catheters should be allowed on the market with 510(k)s rather than the current PMA standard

PTCA Catheter Downclassification Carries Unresolved Safety Issues - Panel

Postmarket surveillance requirements should be part of any decision to downclassify percutaneous transluminal coronary angioplasty (PTCA) balloon catheters from Class III to Class II, according to FDA's Circulatory System Devices Panel.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts